Company news

Share this article:
San Diego, CA-based Adventrx Pharmaceuticals announced that it will terminate a total of nine employees, 27% of its workforce, including one sales position as part of a comprehensive restructuring initiative. Evan M. Levine resigned his positions as CEO and president, effective October 17, 2008. Going forward, the company said that it will focus its resources solely on the development and regulatory approvals of ANX-530 (vinorelbine emulsion) and ANX- 514 (docetaxel emulsion). The company has discontinued active work on all product candidates other than ANX-530 and ANX-514, including its CoFactor program. Patients currently receiving CoFactor will continue to receive treatment.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.